Cargando…

Long-term prognostic value of longitudinal measurements of blood neurofilament levels

OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value...

Descripción completa

Detalles Bibliográficos
Autores principales: Häring, Dieter A., Kropshofer, Harald, Kappos, Ludwig, Cohen, Jeffrey A., Shah, Anuja, Meinert, Rolf, Leppert, David, Tomic, Davorka, Kuhle, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428358/
https://www.ncbi.nlm.nih.gov/pubmed/32817406
http://dx.doi.org/10.1212/NXI.0000000000000856
_version_ 1783571058078515200
author Häring, Dieter A.
Kropshofer, Harald
Kappos, Ludwig
Cohen, Jeffrey A.
Shah, Anuja
Meinert, Rolf
Leppert, David
Tomic, Davorka
Kuhle, Jens
author_facet Häring, Dieter A.
Kropshofer, Harald
Kappos, Ludwig
Cohen, Jeffrey A.
Shah, Anuja
Meinert, Rolf
Leppert, David
Tomic, Davorka
Kuhle, Jens
author_sort Häring, Dieter A.
collection PubMed
description OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value when combined with clinical and MRI measures. METHODS: This analysis included continuously fingolimod-treated patients with RRMS from the 24-month FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS)/12-month Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) phase 3 trials and their long-term extension, LONGTERMS. Patients were classified into high (≥30 pg/mL, n = 110) and low (<30 pg/mL, n = 164) NfL categories based on the baseline (BL) NfL value or the geometric mean NfL(long) calculated over 12 and 24 months to predict disability-related outcomes and brain volume loss (BVL). The additional prognostic value of NfL was quantified using the area under the receiver operating characteristic (ROC) curve. RESULTS: A single high (vs low) NfL measure at BL was prognostic of a higher risk of reaching Expanded Disability Status Scale (EDSS) score ≥4 earlier (hazard ratio [HR] = 2.19; 95% CI = 1.21–3.97) and higher BVL over 120 months (difference: −1.12%; 95% CI = −2.07 to −0.17). When NfL(long) was measured over 24 months, high NfL was associated with a higher risk of reaching EDSS score ≥4 (HR = 7.91; 95% CI = 2.99–20.92), accelerated 6-month confirmed disability worsening (HR = 3.14; 95% CI = 1.38–7.11), and 20% worsening in the Timed 25-Foot Walk Test (HR = 3.05; 95% CI = 1.38–6.70). Area under the ROC curve was consistently highest in models combining NfL with clinical and MRI measures. CONCLUSIONS: NfL(long) had a higher prognostic value than single NfL assessments on long-term outcomes in RRMS. Combining it with clinical and MRI measures increased sensitivity and specificity to predict long-term disease outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that NfL(long) was more strongly associated with long-term outcomes than single NfL assessments in patients with RRMS.
format Online
Article
Text
id pubmed-7428358
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74283582020-08-25 Long-term prognostic value of longitudinal measurements of blood neurofilament levels Häring, Dieter A. Kropshofer, Harald Kappos, Ludwig Cohen, Jeffrey A. Shah, Anuja Meinert, Rolf Leppert, David Tomic, Davorka Kuhle, Jens Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value when combined with clinical and MRI measures. METHODS: This analysis included continuously fingolimod-treated patients with RRMS from the 24-month FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS)/12-month Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) phase 3 trials and their long-term extension, LONGTERMS. Patients were classified into high (≥30 pg/mL, n = 110) and low (<30 pg/mL, n = 164) NfL categories based on the baseline (BL) NfL value or the geometric mean NfL(long) calculated over 12 and 24 months to predict disability-related outcomes and brain volume loss (BVL). The additional prognostic value of NfL was quantified using the area under the receiver operating characteristic (ROC) curve. RESULTS: A single high (vs low) NfL measure at BL was prognostic of a higher risk of reaching Expanded Disability Status Scale (EDSS) score ≥4 earlier (hazard ratio [HR] = 2.19; 95% CI = 1.21–3.97) and higher BVL over 120 months (difference: −1.12%; 95% CI = −2.07 to −0.17). When NfL(long) was measured over 24 months, high NfL was associated with a higher risk of reaching EDSS score ≥4 (HR = 7.91; 95% CI = 2.99–20.92), accelerated 6-month confirmed disability worsening (HR = 3.14; 95% CI = 1.38–7.11), and 20% worsening in the Timed 25-Foot Walk Test (HR = 3.05; 95% CI = 1.38–6.70). Area under the ROC curve was consistently highest in models combining NfL with clinical and MRI measures. CONCLUSIONS: NfL(long) had a higher prognostic value than single NfL assessments on long-term outcomes in RRMS. Combining it with clinical and MRI measures increased sensitivity and specificity to predict long-term disease outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that NfL(long) was more strongly associated with long-term outcomes than single NfL assessments in patients with RRMS. Lippincott Williams & Wilkins 2020-08-12 /pmc/articles/PMC7428358/ /pubmed/32817406 http://dx.doi.org/10.1212/NXI.0000000000000856 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Häring, Dieter A.
Kropshofer, Harald
Kappos, Ludwig
Cohen, Jeffrey A.
Shah, Anuja
Meinert, Rolf
Leppert, David
Tomic, Davorka
Kuhle, Jens
Long-term prognostic value of longitudinal measurements of blood neurofilament levels
title Long-term prognostic value of longitudinal measurements of blood neurofilament levels
title_full Long-term prognostic value of longitudinal measurements of blood neurofilament levels
title_fullStr Long-term prognostic value of longitudinal measurements of blood neurofilament levels
title_full_unstemmed Long-term prognostic value of longitudinal measurements of blood neurofilament levels
title_short Long-term prognostic value of longitudinal measurements of blood neurofilament levels
title_sort long-term prognostic value of longitudinal measurements of blood neurofilament levels
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428358/
https://www.ncbi.nlm.nih.gov/pubmed/32817406
http://dx.doi.org/10.1212/NXI.0000000000000856
work_keys_str_mv AT haringdietera longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT kropshoferharald longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT kapposludwig longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT cohenjeffreya longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT shahanuja longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT meinertrolf longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT leppertdavid longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT tomicdavorka longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels
AT kuhlejens longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels